Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractLaboratory and epidemiological data have linked vitamin D to breast cancer prevention. Beside dietary intake, endogenous production of vitamin D substantially contributes to a subject's vitamin D status. Most studies, however, have assessed dietary intake only. Although differential effects of vitamin D on premenopausal and postmenopausal breast cancer have been discussed, this is the first study to investigate the association of plasma 25-hydroxyvitamin D [25(OH)D], as indicator of the overall vitamin D status, with breast cancer risk with restriction to premenopausal women only. We used data of a population-based case-control study comprising 289 cases and 595 matched controls. Information on sociodemographic and breast cancer risk factors was collected by questionnaire and plasma 25(OH)D was measured by enzyme immunoassay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. We observed a significant inverse association between breast cancer risk and plasma 25(OH)D concentrations. Compared with the lowest category (<30 nmol/L), the ORs (95% CI) for the upper categories (30-45, 45-60, >or=60 nmol/L) were 0.68 (0.43-1.07), 0.59 (0.37-0.94) and 0.45 (0.29-0.70), respectively (p(trend) = 0.0006). The association was shown to be nonlinear (p(nonlinearity) = 0.06) in fractional polynomial analysis with a stronger effect in women at low plasma 25(OH)D levels, providing some evidence of a threshold effect (at circa 50 nmol/L). The association was stronger in progesterone receptor negative tumors, with suggestive evidence of effect heterogeneity (p(heterogeneity) = 0.05, case-only model). Our findings support a protective effect of vitamin D for premenopausal breast cancer.
CitationInt. J. Cancer 2009, 124 (1):250-255
- Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study.
- Authors: Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J
- Issue date: 2008 Jan
- Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study.
- Authors: Abbas S, Linseisen J, Chang-Claude J
- Issue date: 2007
- Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II.
- Authors: Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE
- Issue date: 2011 May 11
- Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study.
- Authors: Scarmo S, Afanasyeva Y, Lenner P, Koenig KL, Horst RL, Clendenen TV, Arslan AA, Chen Y, Hallmans G, Lundin E, Rinaldi S, Toniolo P, Shore RE, Zeleniuch-Jacquotte A
- Issue date: 2013 Feb 26
- Serum 25-hydroxyvitamin D and risk of breast cancer: results of a large population-based case-control study in Mexican women.
- Authors: Fedirko V, Torres-Mejía G, Ortega-Olvera C, Biessy C, Angeles-Llerenas A, Lazcano-Ponce E, Saldaña-Quiroz VA, Romieu I
- Issue date: 2012 Jul